Biogen [BIIB] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Biogen Inc.

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Biogen Inc. wins in 9 metrics, Johnson & Johnson wins in 11 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biogen Inc. Johnson & Johnson Better
P/E Ratio (TTM) 20.96 20.49 Johnson & Johnson
Price-to-Book Ratio 1.48 6.68 Biogen Inc.
Debt-to-Equity Ratio 36.47 60.50 Biogen Inc.
PEG Ratio -0.18 0.42 Johnson & Johnson
EV/EBITDA 8.44 16.84 Biogen Inc.
Profit Margin (TTM) 13.07% 21.83% Johnson & Johnson
Operating Margin (TTM) 19.64% 26.72% Johnson & Johnson
EBITDA Margin (TTM) 19.64% 26.72% Johnson & Johnson
Return on Equity 7.39% 32.87% Johnson & Johnson
Return on Assets (TTM) 6.14% 13.46% Johnson & Johnson
Free Cash Flow (TTM) $1.97B $19.31B Johnson & Johnson
Dividend Yield N/A 2.09% N/A
1-Year Return 51.01% 45.18% Biogen Inc.
Price-to-Sales Ratio (TTM) 2.73 5.66 Biogen Inc.
Enterprise Value $30.41B $574.25B Johnson & Johnson
EV/Revenue Ratio 3.08 5.96 Biogen Inc.
Gross Profit Margin (TTM) 78.26% 67.56% Biogen Inc.
Revenue per Share (TTM) $68 $40 Biogen Inc.
Earnings per Share (Diluted) $8.79 $11.04 Johnson & Johnson
Beta (Stock Volatility) 0.16 0.33 Biogen Inc.
Short % of Float 3.37% 1.03% Johnson & Johnson

Biogen Inc. vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

BIIB
JNJ

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biogen Inc.3.78%-2.20%0.87%0.41%4.80%6.19%
Johnson & Johnson0.31%-3.15%-0.57%-10.32%8.52%7.51%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biogen Inc.51.01%-34.71%-31.50%-32.47%107.63%310.82%
Johnson & Johnson45.18%43.55%35.77%96.35%240.94%270.97%

Performance & Financial Health Analysis: Biogen Inc. vs Johnson & Johnson

MetricBIIBJNJ
Market Information
Market Cap i$27.06B$555.84B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i1,101,5038,370,566
90 Day Avg. Volume i1,198,6547,752,965
Last Close$195.96$223.57
52 Week Range$121.05 - $205.97$149.04 - $251.71
% from 52W High-4.86%-11.18%
All-Time High$480.18 (Mar 16, 2015)$251.71 (Mar 02, 2026)
% from All-Time High-59.19%-11.18%
Growth Metrics
Quarterly Revenue Growth-0.07%0.10%
Quarterly Earnings Growth-0.07%-0.52%
Financial Health
Profit Margin (TTM) i0.13%0.22%
Operating Margin (TTM) i0.20%0.27%
Return on Equity (TTM) i0.07%0.33%
Debt to Equity (MRQ) i36.4760.50
Cash & Liquidity
Book Value per Share (MRQ)$124.37$33.87
Cash per Share (MRQ)$26.00$8.34
Operating Cash Flow (TTM) i$2.20B$22.21B
Levered Free Cash Flow (TTM) i$1.98B$43.47B
Dividends
Last 12-Month Dividend Yield iN/A2.09%
Last 12-Month Dividend iN/A$5.20

Valuation & Enterprise Metrics Analysis: Biogen Inc. vs Johnson & Johnson

MetricBIIB (Apr 26, 2026)JNJ (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.9620.49
Forward P/E i11.5117.80
PEG Ratio i-0.180.42
Price to Sales (TTM) i2.735.66
Price to Book (MRQ) i1.486.68
Market Capitalization
Market Capitalization i$27.06B$555.84B
Enterprise Value i$30.41B$574.25B
Enterprise Value Metrics
Enterprise to Revenue i3.085.96
Enterprise to EBITDA i8.4416.84
Risk & Other Metrics
Beta i0.160.33
Book Value per Share (MRQ) i$124.37$33.87

Financial Statements Comparison: Biogen Inc. vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIIB (2025)JNJ (2025)
Revenue/Sales i9.89B94.19B
Cost of Goods Sold i2.40B30.26B
COGS % of Revenue i24.3%32.1%
Gross Profit i7.49B63.94B
Gross Margin i75.7%67.9%
Research & Development i1.78B14.67B
Operating Income (EBIT) i2.47B25.60B
Operating Margin i25.0%27.2%
EBITDA i3.40B35.16B
EBITDA Margin i34.4%37.3%
Pre-Tax Income i1.56B32.58B
Pre-Tax Income % of Revenue i15.7%34.6%
Income Tax i263.60M5.78B
Income Tax % of Revenue i2.7%6.1%
Net Income (Profit) i1.29B26.80B
Profit Margin i13.1%28.5%

Balance Sheet & Liquidity Metrics

MetricBIIB (2025)JNJ (2025)
Cash & Equivalents i3.01B19.71B
Total Current Assets i8.97B55.62B
Total Current Assets % of Revenue i90.7%59.1%
Total Current Liabilities i3.35B54.13B
Total Current Liabilities % of Revenue i33.9%57.5%
Long-Term Debt i6.58B39.44B
Long-Term Debt % of Revenue i66.5%41.9%
Total Shareholders Equity i18.26B81.54B
Retained Earnings i20.55BN/A
Retained Earnings % of Revenue i207.8%0.0%
Property, Plant & Equipment i265.40M0

Cash Flow Statement Comparison

MetricBIIB (2025)JNJ (2025)
Operating Cash Flow i1.95B22.21B
Operating Cash Flow % of Revenue i19.8%23.6%
Capital Expenditures i-153.80M-4.83B
Free Cash Flow i1.97B19.31B
FCF Margin i19.9%20.5%
Debt Repayment i-1.75B-14.09B
Common Stock Repurchase iN/A-5.95B

Short Interest & Institutional Ownership Analysis

MetricBIIBJNJ
Shares Short i3.83M22.27M
Short Ratio i3.962.90
Short % of Float i3.37%1.03%
Shares Outstanding i146.80M2.41B
Float Shares i146.28M2.41B
% Held by Insiders i0.17%0.06%
% Held by Institutions i98.82%75.84%
% Held by Public i1.01%24.10%

Dividend Analysis & Yield Comparison: Biogen Inc. vs Johnson & Johnson

MetricBIIBJNJ
Last 12-Month Dividend iN/A$5.20
Last 12-Month Dividend Yield iN/A2.09%
3-Year Avg Annual Dividend iN/A$4.97
3-Year Avg Dividend Yield iN/A0.74%
3-Year Total Dividends iN/A$14.92
Ex-Dividend DateN/AFeb 24, 2026